Friday 6 November 2026 Export VCYT’s income statement to Excel — free account

Veracyte, Inc.

VCYT Healthcare Diagnostics & Research

Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024.

Revenue: +15.1%
EPS: +62.5%
Free cash flow: −9.63%

Quarter to September 2026, against a year earlier

24.18 0.18 +0.75%

Follow VCYT

Alert me

Market cap: $1.9B
P/E: 15.2×
Fwd P/E: 45.2×
Dividend yield: —
F-score: 8/9
Altman Z: 21.08
Beneish M: −2.66
Dividend safety: n/a

Overview

Veracyte, Inc. (VCYT) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Veracyte, Inc. (VCYT) trades at a P/S ratio of 3.3×. Over the past ten years it has ranged from 2.4× (March 2016) to 36.9× (February 2021); the current reading is higher than 11% of that period. That is below the Diagnostics & Research industry median of 4.2× and in line with the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/VCYT/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Veracyte, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/VCYT/metrics/ps-ratio">Veracyte, Inc. (VCYT) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	6.4×	(5.85%)
FY2024	6.8×	23.25%
FY2023	5.5×	0.87%
FY2022	5.5×	(57.11%)
FY2021	12.7×	(42.55%)
FY2020	22.2×	107.23%
FY2019	10.7×	111.44%
FY2018	5.1×	59.75%
FY2017	3.2×	(8.88%)
FY2016	3.5×	(8.03%)

Period	P/S ratio	Change
Sep 2026	6.4×	(23.79%)
Jun 2026	8.4×	76.75%
Mar 2026	4.7×	(26.08%)
Dec 2025	6.4×	17.20%
43 more quarters	Free account

Against its own ten years

Low 2.4× High 36.9×

Ten-year median 5.6×

Current reading's percentile 12

Company	P/S ratio
RDNT RadNet, Inc. compare	2.7×
NEO NeoGenomics, Inc. compare	2.7×
VCYT Veracyte, Inc.	3.3×
SHC Sotera Health Company compare	3.7×
WGS GeneDx Holdings Corp. compare	4.2×
CDNA CareDx, Inc. compare	8.1×
BLLN BillionToOne, Inc. compare	12.1×
ADPT Adaptive Biotechnologies Corporation compare	14.5×
GRAL GRAIL, Inc. compare	34.9×
Diagnostics & Research industry median	4.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Veracyte, Inc. (VCYT) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on VCYT

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on VCYT

Stockrow Weekly